MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (October 2015)

26 slides from MabVax Therapeutics's investor presentation, Oct 22, 2015

  1. Slide 1: MabVax Therapeutics Corporate Presentation

    Slide 1: MabVax Therapeutics Corporate Presentation

    NY/| MabVax herapeutics DIFFERENTIATED IMMUNO-ONCOLOGY DEVELOPMENT COMPANY CORPORATE PRESENTATION OTCQB: MBVX = ee

  2. Slide 2: Disclaimer: Forward Looking Statements

    Slide 2: Disclaimer: Forward Looking Statements

    Disclaimer Forward Looking Statements ‘This presentation contai s forward-looking statements and projections. The company makes no this information ot, in the f the project is i its own independent investigation. il is, her, or Tt must be recognized that estimates of the company actual results. In p

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    INVESTMENT HIGHLIGHTS ‘Complementary Immuno- ‘Oncology Technologies = Cancer vaccine program supported by multiple NIH grants Substantial Near-Term . Clinical Pipeline expected in late 2016 Novel Targets Mivresvex

  4. Slide 4: Robust Pipeline with Multiple Near-Term Milestones

    Slide 4: Robust Pipeline with Multiple Near-Term Milestones

    ROBUST PIPELINE WITH MULTIPLE NEAR-TERM MILESTONE: Antibody Program Pr Tndicat tn Phase? | Phase3 7 Fa i I 2 g : 4 i ; i g 4 ; Q Newoblastoma NANT, Melanoma, bres, | > SCL, M Mabver

  5. Slide 5: Recent Achievements

    Slide 5: Recent Achievements

    RECENT ACHIEVEMENTS PET product + + oF + + + oF + +

  6. Slide 6: Antibody Program

    Slide 6: Antibody Program

    Antibody Program DISCOVERING FULLY-HUMAN ANTIBODIES FROM THE SANCER PATIE

  7. Slide 7: Discovering Fully-Human Antibodies from the Immune Response

    Slide 7: Discovering Fully-Human Antibodies from the Immune Response

    IMMUNE RESPONSE FROM MANY VACCINATED PATIENT: f wai ese 4 Repeatedly vaccinate to drive and achieve A re Rasps sensi antibody response é full adv range of unigu anemic of human immune system Delivered to roduce highly eta tid protective Multiple Patients vetibod (Range 7 to 68) anthodtes, 1m patient

  8. Slide 8: Lead Antibody Program Meets Significant Need in Metastatic Pancreatic and Colon Cancer

    Slide 8: Lead Antibody Program Meets Significant Need in Metastatic Pancreatic and Colon Cancer

    LEAD ANTIBODY PROGRAM MEETS SIGNIFICANT NEED IN METASTATIC PANCREATIC AND COLON CANCER —— colon cancer ~ Target is the most extensively studied and clinically useful biomarker for pancreatic cancer ~ Only currently validated assay approved by F 7 attractive molecular target spread! = Increased expre

  9. Slide 9: HuMab 5B1 Antibody Target Significantly Overexpressed On Multiple Cancers

    Slide 9: HuMab 5B1 Antibody Target Significantly Overexpressed On Multiple Cancers

    HuMab 5B1 Antibody Target Significantly Overexpressed On Multiple Cancer. = Pancreas, duct Sigmoid colon, Lung, adenocarcinoma, daenocacnome, tage carcinoma stage 6 () Stage 18 eee r preereses ete S sy Urinary bladder, mu: Ovary, metastati yeh node, metastatic adenocarcinomo, stage carcinoma from co

  10. Slide 10: Minimal Staining in Normal Tissues Enhances Safety Profile

    Slide 10: Minimal Staining in Normal Tissues Enhances Safety Profile

    MINIMAL STAINING IN NORMAL TISSUES ENHANCES SAFETY PROFILE Brain neg Breast + Kidney neg liver neg lung neg lymph node nee Muscle neg Pancreas + Placenta neg skin neg neg Stomach neg Unpublished data. Allwork done at Pathology Department MSKCC Mivenvex Positive cells are restricted to the secretory

  11. Slide 11: HuMab 5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    Slide 11: HuMab 5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    HuMab 5B1 Demonstrates Substantial Potentiation of Anti- Tumor Effect of SOC Chemotherapy Relative Tumor Growth at Day 42 BxPC3 Xenograft Model § 10 z : & % “Oe ge 8 Be

  12. Slide 12: HuMab 5B1-PET Improves Imaging Compared to Standard Agent

    Slide 12: HuMab 5B1-PET Improves Imaging Compared to Standard Agent

    HUMAB 5B1-PET IMPROVES IMAGING COMPARED TO STANDARD AGENT IN USE TODAY Journal of Nuclear Medicine Nov. 2013) segisttion computed ‘enon (Ct) and pr cio a EDG.IET ony (eh) depos rina enor ofthe rae wih gh pein Wy Product All work done in coloration with and in the hb of Jasoa S. Levis, PAD. Member, M

  13. Slide 13: 5B1 Radioimmunotherapy in BxPC3 Pancreatic Tumor Model

    Slide 13: 5B1 Radioimmunotherapy in BxPC3 Pancreatic Tumor Model

    5B1 RADIOIMMUNOTHERAPY IN BXPC3 PANCREATIC TUMOR MODEL E Do: Radi immunotherapy Dose Selection re: iced) nie *71LU-CHX: ATPASE (75 ci) SE imcuccix-ae DTPA! (480 yo) Y-CHX+ preset pea, yTPA-5B1 (260 Ci) Key Point 5B1 based RIT agents verve sod at sepesie tumor gro Normalized Tumor Volume sl and cal i

  14. Slide 14: HuMab 5B1 Clinical Candidate Selection Summary

    Slide 14: HuMab 5B1 Clinical Candidate Selection Summary

    HUMaAB 5B1 CLINICAL CANDIDATE SELECTION SUMMARY ¢# HuMab 5B1-T1: Lead 5B1 v v Y Potent cancer cell killing “ , , v v Y Efficacy as a sadioimmunotherapy agent ¢@ ®ZrHuMab 5B1: Lead 5B1 Program Diagnostic Antibody v P78 ‘og Sena 5 Concl . an antibody drug conjugate Mivenvex

  15. Slide 15: Market Opportunity Focusing on Metastatic Pancreatic and Colon Cancer

    Slide 15: Market Opportunity Focusing on Metastatic Pancreatic and Colon Cancer

    MARKET OPPORTUNITY FOCUSING ON METASTATIC PANCREATIC AND COLON CA’ —$—_—_— Significant Unmet Medical Need with Billion Dollar Potential Therapeutic Product Diagnostic Product ¢ colon cancer patients each year each year and 80% have metastatic 5 year survival rate is less than 10% disease 4 Most adva

  16. Slide 16: Next Steps in Building Value with Antibody Program

    Slide 16: Next Steps in Building Value with Antibody Program

    NEXT STEPS IN BUILDING VALUE WITH ANTIBODY PROGRAM oe ee © to 18 months + < Mivenvex 16

  17. Slide 17: Therapeutic Vaccine Program

    Slide 17: Therapeutic Vaccine Program

    Therapeutic Vaccine Program ‘VACCINATING PATIENTS TO ELICIT A PROTECTIVE ANTIBODY RESPONSE AIMED AT KILLING RESIDUAL DISEASE

  18. Slide 18: Sarcoma Vaccine POC Phase II Results Anticipated 2016

    Slide 18: Sarcoma Vaccine POC Phase II Results Anticipated 2016

    SARCOMA VACCINE POC PHASE II RESULTS ANTICIPATED 2016 ‘Sarcoma Incidence And Prevalence — 5,290 deaths per year in es Recurrence rates up to 3230 Ss suviine Patents new cos ¢ Clinical Program Status of 136 patients at 13 sites ‘lly enrolled with all patients fully vaccinated = Monitoring for overall

  19. Slide 19: Ovarian Vaccine POC Phase II Results

    Slide 19: Ovarian Vaccine POC Phase II Results

    A OVARIAN VACCINE POC PHASE II RESULT! Prevalence — 13,850 deaths per year in the US. sung Patents new Cases ¢ Clinical Program Status — Fully enrolled and all patients vaccinated = Monitoring for overall survival ¢ Commercial Opportunity non-recombinant components M MabVars

  20. Slide 20: Neuroblastoma Vaccine Program IND

    Slide 20: Neuroblastoma Vaccine Program IND

    Can ‘VACCINE PROGRAM IND N 2012015 ¢ Difficult disease = 700 new cases per year US remission — Treatment well tolerated ¢ Transition to Phase 2 Clinical Trial YA in 2014 Orphan Drug status granted by = Single study approval possible = Launch Phase IT study 2016 (Cl Cans Res 2014:2021375-1382. bled F

  21. Slide 21: MabVax Key Anticipated Milestones

    Slide 21: MabVax Key Anticipated Milestones

    MABVAX KEy ANTICIPATED MILESTONES ‘Neuroblastoma iitite P2 Mivenvex

  22. Slide 22: Robust Intellectual Property

    Slide 22: Robust Intellectual Property

    ROBUST INTELLECTUAL PROPERTY + methods of use + methods of use oy Mivenvex

  23. Slide 23: Strong Management Team and Board of Directors

    Slide 23: Strong Management Team and Board of Directors

    STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J:David Hansen Founder, President Board Member Mab Brace De Shang Plough, Key BM Philip Livingston, MD. Founder & Chief Science Officer Gregory Hanson Chief Financial Officer Wolfgang Scholz, PhD. Found & Vie President Antibody Discovery Paul Maffuid, Ph

  24. Slide 24: Stock

    Slide 24: Stock

    STOCK Mivenvex "MabVax Therapeutics Holdings, Inc. ro forma Shares Common Stock Outstanding Oct. 5, 2015 (excludes Greer 25,891,075 2,500,000 e381 075 19,149,100 2 5,959,668 1,250,000 7208, 668. Shoe) ‘Common stock ssued and outstanding prior to offering Total fully diluted shares outstanding - excl

  25. Slide 25: Near-Term Milestone

    Slide 25: Near-Term Milestone

    NEAR-TERM MILESTONE COMPANY WITH + + 1 applications Poll capital requirements going forward Inc. OTCQB: MBVX Mivenvex

  26. Slide 26: MabVax Therapeutics Company Contacts

    Slide 26: MabVax Therapeutics Company Contacts

    Mi MabVax herapeutics Di FERENTIATED IMMUNO-ONCOLOGY DEVELOPMENT COMPANY System To Diagnose and Treat Cancer Company Contacts en ory Hanson President and CEO Chief Financial Officer mei com gregoryhanson@mabv 858-259-940: 858-259-9405 x 30:

Source: SEC EDGAR · 8-K filed Oct 22, 2015

More decks from MabVax Therapeutics Holdings Inc